ReviewJournal of biomedicine & biotechnology2010
Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches.
Review in Journal of biomedicine & biotechnology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 50 citations in OpenAlex.
- Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study.Arthritis research & therapy · 2011Trial
- Immunopathogenesis of accelerated atherosclerosis in systemic lupus erythematosus: from innate and adaptive dysregulation to clinical implications.Frontiers in immunology · 2026Review
- Residual Traditional Risk in Non-Traditional Atherosclerotic Diseases.International journal of molecular sciences · 2025Review
- Review
- Dyslipidemia is associated with inflammation and organ involvement in systemic lupus erythematosus.Clinical rheumatology · 2023Article
- Can Micro RNA-24 Affect the Cardiovascular Morbidity in Systemic Lupus Erythematosus by Targeting YKL-40?Reports of biochemistry & molecular biology · 2022Article
- Young mother with lupus and life-altering cardiocerebrovascular nightmare: a case report.European heart journal. Case reports · 2022Article
- Immune mechanisms associated with cardiovascular disease in systemic lupus erythematosus: A path to potential biomarkers.Frontiers in immunology · 2022Review
- Role of microRNAs in the Development of Cardiovascular Disease in Systemic Autoimmune Disorders.International journal of molecular sciences · 2020Review
- IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: Evidence for a dual role.European journal of rheumatology · 2017Article
- 'Atherothrombosis-associated microRNAs in Antiphospholipid syndrome and Systemic Lupus Erythematosus patients'.Scientific reports · 2016Article
- Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions.International journal of clinical rheumatology · 2015Article
- An important role for A20-binding inhibitor of nuclear factor-kB-1 (ABIN1) in inflammation-mediated endothelial dysfunction: an in vivo study in ABIN1 (D485N) mice.Arthritis research & therapy · 2015Article
- Anti-apolipoprotein A-1 antibodies and carotid intima-media thickness in Egyptian women with systemic lupus erythematosus.Clinical rheumatology · 2014Article
- Atherosclerosis in systemic lupus erythematosus.Journal of cardiovascular pharmacology · 2013Review
- Drosophila GPI-mannosyltransferase 2 is required for GPI anchor attachment and surface expression of chaoptin.Visual neuroscience · 2012Article
- Omics Screening for Pharmaceutical Efficacy and Safety in Clinical Practice.Journal of pharmacogenomics & pharmacoproteomics · 2012Article
- Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches.Current allergy and asthma reports · 2012Review
- Cardiovascular risk in systemic autoimmune diseases: epigenetic mechanisms of immune regulatory functions.Clinical & developmental immunology · 2012Review
- Plasmacytoid dendritic cells in atherosclerosis.Frontiers in physiology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE), a chronic multisystem autoimmune disease with a broad range of clinical manifestations, is associated with accelerated atherosclerosis (AT) and increased risk of cardiovascular complications. Relevant factors directly influencing the development of AT comprise immune complex generation, complement activation, and changes in the production and activity of a complex network of cytokines, including type I and II interferons, B lymphocyte stimulator (BLyS), TNFα, IL-6, IL-17 and migration macrophage inhibitor (MIF). Autoantibodies, also responsible for cytokine expression and activation, play a supplementary key role in the development of AT. Genomic and proteomic studies have contributed to the discovery of genes and proteins involved in AT, including some that may be suitable to be used as biomarkers. All that data has allowed the development of new drugs, most of them evaluated in clinical trials: inhibitors of IFN and TNFα, B cell directed therapies, synthetic oligodeoxynucleotides, intravenous immunoglobulin, or statins. The focus of the present paper is to summarize recent evidence showing the role of cytokines in the development of AT in SLE and the rationale, and safety concerns, in the use of combined therapy to prevent AT and cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.